Emily Ko1, Susanna Lee, Annekathryn Goodman. 1. Massachusetts General Hospital, Department of Gynecologic-Oncology, Boston, Massachusetts 02114-2617, USA.
Abstract
BACKGROUND: A case of gemcitabine-induced lung toxicity is reported in a woman with stage IIIc ovarian papillary serous carcinoma. CASE: An 83-year-old woman with stage IIIc ovarian serous papillary carcinoma diagnosed in 2001 underwent suboptimal cytoreductive surgery followed by carboplatin-paclitaxel chemotherapy. Initially in remission following chemotherapy, the disease subsequently progressed over the next 5 years. The patient received gemcitabine palliative chemotherapy. She developed significant pulmonary toxicity consistent with drug-induced interstitial pneumonitis, which improved with steroid therapy. CONCLUSION: Gemcitabine, a second-line chemotherapy agent for the treatment of ovarian cancer, may rarely cause a serious or even fatal condition of pulmonary lung toxicity.
BACKGROUND: A case of gemcitabine-induced lung toxicity is reported in a woman with stage IIIc ovarian papillary serous carcinoma. CASE: An 83-year-old woman with stage IIIc ovarian serous papillary carcinoma diagnosed in 2001 underwent suboptimal cytoreductive surgery followed by carboplatin-paclitaxel chemotherapy. Initially in remission following chemotherapy, the disease subsequently progressed over the next 5 years. The patient received gemcitabine palliative chemotherapy. She developed significant pulmonary toxicity consistent with drug-induced interstitial pneumonitis, which improved with steroid therapy. CONCLUSION:Gemcitabine, a second-line chemotherapy agent for the treatment of ovarian cancer, may rarely cause a serious or even fatal condition of pulmonary lung toxicity.
Authors: Ibrahim Halil Sahin; Alexander I Geyer; Daniel W Kelly; Eileen Mary O'Reilly Journal: Clin Colorectal Cancer Date: 2015-08-22 Impact factor: 4.481